H3-DYNAMICS
15.12.2022 14:34:41 CET | Business Wire | Press release
H3 Dynamics and HyLight have joined forces to bring new long range, sustainable and quiet unmanned airships to a range of commercial applications. Traditionally, airships use combustion engines for their propulsion power. With new hydrogen propulsion system developments at H3 Dynamics, HyLight’s new breed of airships will now offer long-range zero emission flight and open a whole new category in air mobility. The two companies share a common goal, to decarbonize the aerial industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005555/en/
HyLight’s compact airship is powered by H3 Dynamics hydrogen air-mobility power systems
HyLight and H3 Dynamics started working together several months ago in France, and HyLight have now achieved a first successful hydrogen-electric flight test campaign in Milan, Italy. HyLight is an up and coming french start-up and one of the very few companies in the world that was able to demonstrate hydrogen as a viable power supply for small unmanned airships in real conditions. This was made possible with H3 Dynamics’ aerospace-grade hydrogen fuel cells - the smallest and lightest in the world - have pioneered hydrogen flight research from as early 2006.
HyLight’s unmanned airships move slowly but don’t need to consume any power to stay aloft. They can operate for days at a time with heavier payloads compared to conventional drones, to conduct long range inspection of critical energy assets like power-lines & pipelines or scan industrial infrastructure over long distances. Airships could also hover around specific areas to provide critical connectivity for large scale industrial sites - or provide vital communications after a natural disaster.
Based in Toulouse, H3 Dynamics is set on decarbonizing air mobility with clean hydrogen-electric propulsion, starting with enabling smaller unmanned systems - whether fixed wing, multi-rotor or VTOL platforms. Its ultra-light power technology is bringing new long electric flight durations to the global unmanned aviation market, which is set to reach $38 Billion by 2027.
Earlier this year H3 Dynamics flew the world’s first distributed hydrogen-electric nacelles on a small unmanned platform, proving the potential for larger size systems in bigger aircraft. H3 Dynamics has since become part of the “Toulouse Pioneers” group linked to the Aerospace History Museum “L’Envol des Pionniers”. The company plans to scale its solutions to larger unmanned and manned aviation platforms over the coming years.
HyLight will leverage H3 Dynamics’ international presence covering Europe, North and South America as well as Asia and Australia to bring “made in France” hydrogen-electric airships to the global market.
About HyLight: https://www.hylight.aero
HyLight wants to decarbonize the aerial data industry by providing long-range aerial data collection and analysis services using its unmanned airship systems for the inspection of power lines, pipelines, and railways. Its airship come with hydrogen electric propulsion making them sustainable, silent, efficient, and long-range to cover large areas or distances. The company was started in France and has recently demonstrated the first flight of its hydrogen-electric platform. HyLight was selected to participate in the 1st Batch of the acceleration program of Berkeley SkyDeck Europe, Milano ; the company is also a member of the Hub Drone Systematic and U-LTA and has been financially supported by La Région Grand Est in France.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is based in Toulouse, Austin and Singapore - and is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. The company’s initial commercial focus is on the scale up of autonomous digital services that link to networks of charging stations for off-the-shelf battery-drones, making way for BVLOS hydrogen UAS capability. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom